Nature Communications (Aug 2022)
Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment
Abstract
The tumour microenvironment in mTORC1 hyperactive cancers remains poorly characterised. Here, integrative analysis in tuberous sclerosis complex tumours with mTORC1 hyperactivity suggests distinct cell states associated with rapamycin resistance and immune modulation.